Therapeutic targeting of the angiopoietin-TIE pathway (Q39321127)

11 September 2017

1 reference

title

Therapeutic targeting of the angiopoietin-TIE pathway (English)

1 reference

11 September 2017

Pipsa Saharinen

1

1 reference

PubMed ID

28529319

11 September 2017

Lauri Eklund

series ordinal

2

1 reference

PubMed ID

28529319

11 September 2017

Kari Alitalo

series ordinal

3

1 reference

11 September 2017

19 May 2017

1 reference

Nature Reviews Drug Discovery

11 September 2017

1 reference

11 September 2017

16

1 reference

11 September 2017

9

1 reference

11 September 2017

635-661

1 reference

https://scigraph.springernature.com/pub.10.1038/nrd.2016.278

11 September 2017

0 references

cites work

Recent molecular discoveries in angiogenesis and antiangiogenic therapies in cancer

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.278

Molecular pathogenesis of retinal and choroidal vascular diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.278

Ten years of anti-vascular endothelial growth factor therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.278

Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.278

Control of vascular morphogenesis and homeostasis through the angiopoietin-Tie system

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.278

The complex role of angiopoietin-2 in the angiopoietin-tie signaling pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.278

Angiopoietin signaling in the vasculature

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.278

VEGF and angiopoietin signaling in tumor angiogenesis and metastasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.278

A novel endothelial cell surface receptor tyrosine kinase with extracellular epidermal growth factor homology domains

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.278

Tie2 identifies a hematopoietic lineage of proangiogenic monocytes required for tumor vessel formation and a mesenchymal population of pericyte progenitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.278

Autocrine and paracrine angiopoietin 1/Tie-2 signaling promotes muscle satellite cell self-renewal

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.278

Self-renewal of a purified Tie2+ hematopoietic stem cell population relies on mitochondrial clearance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.278

Multiple angiopoietin recombinant proteins activate the Tie1 receptor tyrosine kinase and promote its interaction with Tie2

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.278

Differential function of Tie2 at cell-cell contacts and cell-substratum contacts regulated by angiopoietin-1

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.278

Angiopoietins assemble distinct Tie2 signalling complexes in endothelial cell-cell and cell-matrix contacts

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.278

Tie1 controls angiopoietin function in vascular remodeling and inflammation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.278

The Orphan Receptor Tie1 Controls Angiogenesis and Vascular Remodeling by Differentially Regulating Tie2 in Tip and Stalk Cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.278

Tie1 deletion inhibits tumor growth and improves angiopoietin antagonist therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.278

Orchestral actions of angiopoietin-1 in vascular regeneration

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.278

The endothelial receptor tyrosine kinase Tie1 activates phosphatidylinositol 3-kinase and Akt to inhibit apoptosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.278

Angiopoietin-1 modulates endothelial cell function and gene expression via the transcription factor FKHR (FOXO1).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.278

FOXO1 couples metabolic activity and growth state in the vascular endothelium

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.278

Leakage-resistant blood vessels in mice transgenically overexpressing angiopoietin-1

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.278

Somatic mutations in angiopoietin receptor gene TEK cause solitary and multiple sporadic venous malformations

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.278

Somatic Activating PIK3CA Mutations Cause Venous Malformation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.278

Somatic PIK3CA mutations as a driver of sporadic venous malformations.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.278

Somatic activating mutations in Pik3ca cause sporadic venous malformations in mice and humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.278

The Schlemm's canal is a VEGF-C/VEGFR-3-responsive lymphatic-like vessel

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.278

A lymphatic defect causes ocular hypertension and glaucoma in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.278

Angiopoietin receptor TEK mutations underlie primary congenital glaucoma with variable expressivity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.278

Angiopoietin-1 is an antipermeability and anti-inflammatory agent in vitro and targets cell junctions

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.278

Angiopoietin-1 requires IQ domain GTPase-activating protein 1 to activate Rac1 and promote endothelial barrier defense

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.278

Angiopoietin-1 prevents VEGF-induced endothelial permeability by sequestering Src through mDia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.278

The Tie-2 ligand angiopoietin-2 is stored in and rapidly released upon stimulation from endothelial cell Weibel-Palade bodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.278

Angiopoietin-2, a natural antagonist for Tie2 that disrupts in vivo angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.278

Regulation of angiopoietin-2 mRNA levels in bovine microvascular endothelial cells by cytokines and hypoxia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.278

The angiopoietin-2 gene of endothelial cells is up-regulated in hypoxia by a HIF binding site located in its first intron and by the central factors GATA-2 and Ets-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.278

Yes-associated protein regulates endothelial cell contact-mediated expression of angiopoietin-2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.278

Drug Repurposing Screen Identifies Foxo1-Dependent Angiopoietin-2 Regulation in Sepsis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.278

Angiopoietin-2 sensitizes endothelial cells to TNF-alpha and has a crucial role in the induction of inflammation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.278

Excess circulating angiopoietin-2 may contribute to pulmonary vascular leak in sepsis in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.278

Endothelial destabilization by angiopoietin-2 via integrin β1 activation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.278

Opposing actions of angiopoietin-2 on Tie2 signaling and FOXO1 activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.278

Angiopoietin-2 is required for postnatal angiogenesis and lymphatic patterning, and only the latter role is rescued by Angiopoietin-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.278

Stable interaction between alpha5beta1 integrin and Tie2 tyrosine kinase receptor regulates endothelial cell response to Ang-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.278

Constitutive Association of Tie1 and Tie2 with Endothelial Integrins is Functionally Modulated by Angiopoietin-1 and Fibronectin

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.278

Gln-362 of angiopoietin-2 mediates migration of tumor and endothelial cells through association with α5β1 integrin

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.278

Angiopoietin 2 induces pericyte apoptosis via α3β1 integrin signaling in diabetic retinopathy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.278

Angiopoietin-2 differentially regulates angiogenesis through TIE2 and integrin signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.278

Angiopoietin-2 expression in breast cancer correlates with lymph node invasion and short survival.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.278

Angiopoietin-2 levels are associated with disease progression in metastatic malignant melanoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.278

Identification of serum angiopoietin-2 as a biomarker for clinical outcome of colorectal cancer patients treated with bevacizumab-containing therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.278

The role of angiopoietins as potential therapeutic targets in renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.278

Association of Angiopoietin-2 and Ki-67 Expression with Vascular Density and Sunitinib Response in Metastatic Renal Cell Carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.278

Vessel cooption, regression, and growth in tumors mediated by angiopoietins and VEGF.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.278

Suppression of angiogenesis and tumor growth by selective inhibition of angiopoietin-2

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.278

Effects of angiopoietin-2-blocking antibody on endothelial cell-cell junctions and lung metastasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.278

Complementary actions of inhibitors of angiopoietin-2 and VEGF on tumor angiogenesis and growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.278

Ang-2-VEGF-A CrossMab, a novel bispecific human IgG1 antibody blocking VEGF-A and Ang-2 functions simultaneously, mediates potent antitumor, antiangiogenic, and antimetastatic efficacy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.278

Postsurgical adjuvant tumor therapy by combining anti-angiopoietin-2 and metronomic chemotherapy limits metastatic growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.278

Contrasting actions of selective inhibitors of angiopoietin-1 and angiopoietin-2 on the normalization of tumor blood vessels

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.278

Context-dependent role of angiopoietin-1 inhibition in the suppression of angiogenesis and tumor growth: implications for AMG 386, an angiopoietin-1/2-neutralizing peptibody

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.278

Angiopoietin 1 causes vessel enlargement, without angiogenic sprouting, during a critical developmental period.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.278

Angiopoietin-1 promotes lymphatic sprouting and hyperplasia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.278

Angiopoietin-1 promotes LYVE-1-positive lymphatic vessel formation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.278

Targeting vascular pericytes in hypoxic tumors increases lung metastasis via angiopoietin-2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.278

Role of angiopoietin-2 in adaptive tumor resistance to VEGF signaling blockade.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.278

Ang-2/VEGF bispecific antibody reprograms macrophages and resident microglia to anti-tumor phenotype and prolongs glioblastoma survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.278

Dual inhibition of Ang-2 and VEGF receptors normalizes tumor vasculature and prolongs survival in glioblastoma by altering macrophages.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.278

Targeting VE-PTP activates TIE2 and stabilizes the ocular vasculature

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.278

Effects of vascular-endothelial protein tyrosine phosphatase inhibition on breast cancer vasculature and metastatic progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.278

Recurrent PTPRB and PLCG1 mutations in angiosarcoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.278

Metastasis: from dissemination to organ-specific colonization

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.278

Tumor microenvironment of metastasis and risk of distant metastasis of breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.278

Real-Time Imaging Reveals Local, Transient Vascular Permeability, and Tumor Cell Intravasation Stimulated by TIE2hi Macrophage-Derived VEGFA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.278

Tie2 Expression on Macrophages Is Required for Blood Vessel Reconstruction and Tumor Relapse after Chemotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.278

The calcineurin-NFAT-angiopoietin-2 signaling axis in lung endothelium is critical for the establishment of lung metastases

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.278

Targeting the ANG2/TIE2 axis inhibits tumor growth and metastasis by impairing angiogenesis and disabling rebounds of proangiogenic myeloid cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.278

G-CSF rescues tumor growth and neo-angiogenesis during liver metastasis under host angiopoietin-2 deficiency.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.278

Angiopoietin-1 protects the adult vasculature against plasma leakage.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.278

Angiopoietin-1 decreases plasma leakage by reducing number and size of endothelial gaps in venules.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.278

Angiopoietin-2 is critical for cytokine-induced vascular leakage

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.278

Angiopoietin-2 functions as an autocrine protective factor in stressed endothelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.278

Angiopoietin-1 is essential in mouse vasculature during development and in response to injury

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.278

VE-PTP regulates VEGFR2 activity in stalk cells to establish endothelial cell polarity and lumen formation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.278

Angiopoietin-2-driven vascular remodeling in airway inflammation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.278

Angiopoietin-2 may contribute to multiple organ dysfunction and death in sepsis*

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.278

Dysregulation of the angiopoietin-Tie-2 axis in sepsis and ARDS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.278

Angiopoietin 2 is a partial agonist/antagonist of Tie2 signaling in the endothelium

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.278

The molecular balance between receptor tyrosine kinases Tie1 and Tie2 is dynamically controlled by VEGF and TNFα and regulates angiopoietin signalling

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.278

Acute administration of recombinant Angiopoietin-1 ameliorates multiple-organ dysfunction syndrome and improves survival in murine sepsis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.278

Angiopoietin 2 mediates microvascular and hemodynamic alterations in sepsis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.278

Lung-targeted RNA interference against angiopoietin-2 ameliorates multiple organ dysfunction and death in sepsis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.278

Amelioration of sepsis by TIE2 activation-induced vascular protection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.278

Regulation of angiopoietin expression by bacterial lipopolysaccharide.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.278

The flow dependency of Tie2 expression in endotoxemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.278

Gene control of tyrosine kinase TIE2 and vascular manifestations of infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.278

Host genetic diversity enables Ebola hemorrhagic fever pathogenesis and resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.278

Synergistic actions of blocking angiopoietin-2 and tumor necrosis factor-α in suppressing remodeling of blood vessels and lymphatics in airway inflammation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.278

Role of angiopoietin-2 in corneal lymphangiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.278

Long-term and sustained COMP-Ang1 induces long-lasting vascular enlargement and enhanced blood flow.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.278

Angiopoietin-2 inhibition prevents transplant ischemia-reperfusion injury and chronic rejection in rat cardiac allografts.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.278

Circulating Angiopoietin-2 levels predict mortality in kidney transplant recipients: a 4-year prospective case-cohort study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.278

Angiopoietin-1 Protects Against the Development of Cardiac Allograft Arteriosclerosis

21 January 2018

2 references

https://api.crossref.org/works/10.1038%2FNRD.2016.278

21 January 2018

12 December 2020

Donor Heart Treatment With COMP-Ang1 Limits Ischemia-Reperfusion Injury and Rejection of Cardiac Allografts.

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.278

Recent insights into the cellular biology of atherosclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.278

Specific Induction of tie1 Promoter by Disturbed Flow in Atherosclerosis-Prone Vascular Niches and Flow-Obstructing Pathologies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.278

Laminar shear inhibits tubule formation and migration of endothelial cells by an angiopoietin-2 dependent mechanism

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.278

Tie1 attenuation reduces murine atherosclerosis in a dose-dependent and shear stress-specific manner

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.278

Angiopoietin-2 blocking antibodies reduce early atherosclerotic plaque development in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.278

Endothelial exocytosis of angiopoietin-2 resulting from CCM3 deficiency contributes to cerebral cavernous malformation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.278

Vascular Growth Factors and Glomerular Disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.278

High glucose and elevated fatty acids suppress signaling by the endothelium protective ligand angiopoietin-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.278

Targeted glomerular angiopoietin-1 therapy for early diabetic kidney disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.278

Renoprotective effect of COMP-angiopoietin-1 in db/db mice with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.278

Arterial stiffness in diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.278

Angiopoietin-2-induced arterial stiffness in CKD

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.278

COMP-angiopoietin-1 promotes wound healing through enhanced angiogenesis, lymphangiogenesis, and blood flow in a diabetic mouse model

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.278

COMP-angiopoietin-1 recovers molecular biomarkers of neuropathy and improves vascularisation in sciatic nerve of ob/ob mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.278

Angiopoietin-2 plays an important role in retinal angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.278

Angiopoietin 2 expression in the retina: upregulation during physiologic and pathologic neovascularization

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.278

Angiopoietin-2 enhances retinal vessel sensitivity to vascular endothelial growth factor

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.278

Angiopoietin 1 prevents retinal detachment in an aggressive model of proliferative retinopathy, but has no effect on established neovascularization

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.278

Non-responders to bevacizumab (Avastin) therapy of choroidal neovascular lesions

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.278

Intravitreal bevacizumab and ranibizumab for age-related macular degeneration a multicenter, retrospective study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.278

Ranibizumab for neovascular age-related macular degeneration

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.278

Ranibizumab versus verteporfin for neovascular age-related macular degeneration.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.278

Neurons limit angiogenesis by titrating VEGF in retina

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.278

Angiopoietin-1 suppresses choroidal neovascularization and vascular leakage

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.278

Neovascularization in diabetes and its complications. Unraveling the angiogenic paradox.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.278

Nucleoside diphosphate kinase B deficiency causes a diabetes-like vascular pathology via up-regulation of endothelial angiopoietin-2 in the retina.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.278

A potential role for angiopoietin 2 in the regulation of the blood-retinal barrier in diabetic retinopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.278

Angiopoietin-2 causes pericyte dropout in the normal retina: evidence for involvement in diabetic retinopathy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.278

Sustained inflammation after pericyte depletion induces irreversible blood-retina barrier breakdown

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.278

Intravitreal AAV2.COMP-Ang1 Prevents Neurovascular Degeneration in a Murine Model of Diabetic Retinopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.278

Angiopoietin-1 is regulated by miR-204 and contributes to corneal neovascularization in KLEIP-deficient mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.278

Final results of a phase 3 study of trebananib plus weekly paclitaxel in recurrent ovarian cancer (TRINOVA-1): Long-term survival, impact of ascites, and progression-free survival-2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.278

Treatment of diabetic macular edema with an inhibitor of vascular endothelial-protein tyrosine phosphatase that activates Tie2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.278

Enhanced Benefit in Diabetic Macular Edema from AKB-9778 Tie2 Activation Combined with Vascular Endothelial Growth Factor Suppression

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.278

Angiopoietin-1 alters microvascular permeability coefficients in vivo via modification of endothelial glycocalyx

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.278

Simultaneous targeting of TNF and Ang2 with a novel bispecific antibody enhances efficacy in an in vivo model of arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.278

Angiopoietins have distinct modular domains essential for receptor binding, dimerization and superclustering

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.278

Oligomerization and multimerization are critical for angiopoietin-1 to bind and phosphorylate Tie2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.278

Angiopoietin-1 induces sprouting angiogenesis in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.278

Angiopoietin-1 reduces cerebral blood vessel leakage and ischemic lesion volume after focal cerebral embolic ischemia in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.278

A Designed Angiopoietin-1 Variant, Dimeric CMP-Ang1 Activates Tie2 and Stimulates Angiogenesis and Vascular Stabilization in N-glycan Dependent Manner

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.278

COMP-Ang1: a designed angiopoietin-1 variant with nonleaky angiogenic activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.278

Angiopoietin-1 variant reduces LPS-induced microvascular dysfunction in a murine model of sepsis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.278

Designed angiopoietin-1 variant, COMP-angiopoietin-1, rescues erectile function through healthy cavernous angiogenesis in a hypercholesterolemic mouse

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.278

Intracavernous delivery of a designed angiopoietin-1 variant rescues erectile function by enhancing endothelial regeneration in the streptozotocin-induced diabetic mouse

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.278

The effects of designed angiopoietin-1 variant on lipid droplet diameter, vascular endothelial cell density and metabolic parameters in diabetic db/db mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.278

COMP-angiopoietin-1 enhances skeletal muscle blood flow and insulin sensitivity in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.278

Designed angiopoietin-1 variant, COMP-Ang1, protects against radiation-induced endothelial cell apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.278

COMP-angiopoietin-1 decreases lipopolysaccharide-induced acute kidney injury

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.278

Angiopoietin-1 variant, COMP-Ang1 attenuates hydrogen peroxide-induced acute lung injury

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.278

Angiopoietin-1 protects heart against ischemia/reperfusion injury through VE-cadherin dephosphorylation and myocardiac integrin-β1/ERK/caspase-9 phosphorylation cascade

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.278

COMP-Ang1 stimulates HIF-1α-mediated SDF-1 overexpression and recovers ischemic injury through BM-derived progenitor cell recruitment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.278

Peritubular capillary preservation with COMP-angiopoietin-1 decreases ischemia-reperfusion-induced acute kidney injury

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.278

Cartilage oligometric matrix protein-angiopoietin-1 promotes revascularization through increased survivin expression in dermal endothelial cells of skin grafts in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.278

COMP-Ang1, a chimeric form of Angiopoietin 1, enhances BMP2-induced osteoblast differentiation and bone formation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.278

COMP-angiopoietin1 potentiates the effects of bone morphogenic protein-2 on ischemic necrosis of the femoral head in rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.278

COMP-angiopoietin-1 accelerates bone formation during distraction osteogenesis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.278

The Angiopoietin-1 Variant COMP-Ang1 Enhances BMP2-Induced Bone Regeneration with Recruiting Pericytes in Critical Sized Calvarial Defects

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.278

Vascular endothelial growth factor-angiopoietin chimera with improved properties for therapeutic angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.278

Safety, pharmacokinetics, and antitumor activity of AMG 386, a selective angiopoietin inhibitor, in adult patients with advanced solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.278

Incidence and management of edema associated with trebananib (AMG 386).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.278

Trebananib (AMG 386) in Combination With Sunitinib in Patients With Metastatic Renal Cell Cancer: An Open-Label, Multicenter, Phase II Study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.278

VEGF-dependent plasticity of fenestrated capillaries in the normal adult microvasculature

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.278

Mechanisms of adverse effects of anti-VEGF therapy for cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.278

A novel angiopoietin-2 selective fully human antibody with potent anti-tumoral and anti-angiogenic efficacy and superior side effect profile compared to Pan-Angiopoietin-1/-2 inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.278

Investigation of novel circulating proteins, germ line single-nucleotide polymorphisms, and molecular tumor markers as potential efficacy biomarkers of first-line sunitinib therapy for advanced renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.278

Intrinsic versus microenvironmental regulation of lymphatic endothelial cell phenotype and function

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.278

Axitinib effectively inhibits BCR-ABL1(T315I) with a distinct binding conformation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.278

Angiopoietins 3 and 4: diverging gene counterparts in mice and humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.278

Molecular cloning and characterization of a novel angiopoietin family protein, angiopoietin-3

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.278

Angiopoietin-3, a novel member of the angiopoietin family

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.278

Hypoxia-inducible factor-1 mediates activation of cultured vascular endothelial cells by inducing multiple angiogenic factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.278

Expression of angiopoietins in renal epithelial and clear cell carcinoma cells: regulation by hypoxia and participation in angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.278

Biological characterization of angiopoietin-3 and angiopoietin-4

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.278

Effect of intracavernous administration of angiopoietin-4 on erectile function in the streptozotocin-induced diabetic mouse.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.278

Somatic mutations in exon 17 of the TEK gene in vascular tumors and vascular malformations.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.278

Blue Rubber Bleb Nevus (BRBN) Syndrome Is Caused by Somatic TEK (TIE2) Mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.278

High frequency of mutations of the PIK3CA gene in human cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.278

Clinical and Genetic Aspects of the Segmental Overgrowth Spectrum Due to Somatic Mutations in PIK3CA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.278

Lymphatic and other vascular malformative/overgrowth disorders are caused by somatic mutations in PIK3CA

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.278

Activating PIK3CA alleles and lymphangiogenic phenotype of lymphatic endothelial cells isolated from lymphatic malformations

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.278

Vascular dysmorphogenesis caused by an activating mutation in the receptor tyrosine kinase TIE2

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.278

VE-PTP controls blood vessel development by balancing Tie-2 activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.278

VE-PTP maintains the endothelial barrier via plakoglobin and becomes dissociated from VE-cadherin by leukocytes and by VEGF.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.278

Hereditary cutaneomucosal venous malformations are caused by TIE2 mutations with widely variable hyper-phosphorylating effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.278

Rapamycin improves TIE2-mutated venous malformation in murine model and human subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.278

Common and specific effects of TIE2 mutations causing venous malformations

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.278

Synchronization of endothelial Dll4-Notch dynamics switch blood vessels from branching to expansion

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.278

Identification and functional analysis of endothelial tip cell-enriched genes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.278

Abnormalities in pericytes on blood vessels and endothelial sprouts in tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.278

Abnormalities of Basement Membrane on Blood Vessels and Endothelial Sprouts in Tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.278

The antiinflammatory endothelial tyrosine kinase Tie2 interacts with a novel nuclear factor-kappaB inhibitor ABIN-2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.278

ABIN-2 protects endothelial cells from death and has a role in the antiapoptotic effect of angiopoietin-1

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.278

Angiopoietin-1 induces Kruppel-like factor 2 expression through a phosphoinositide 3-kinase/AKT-dependent activation of myocyte enhancer factor 2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.278

MicroRNA-30 mediates anti-inflammatory effects of shear stress and KLF2 via repression of angiopoietin 2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.278

Suppression and regression of choroidal neovascularization by systemic administration of an alpha5beta1 integrin antagonist

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.278

Ligand oligomerization state controls Tie2 receptor trafficking and angiopoietin-2-specific responses.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.278

Pericyte migration: a novel mechanism of pericyte loss in experimental diabetic retinopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.278

Suppression of Tie-1 in endothelial cells in vitro induces a change in the genome-wide expression profile reflecting an inflammatory function

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.278

Receptor tyrosine kinase Tie-1 overexpression in endothelial cells upregulates adhesion molecules

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.278

Dissociation of VE-PTP from VE-cadherin is required for leukocyte extravasation and for VEGF-induced vascular permeability in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.278

Lymphatic regulator PROX1 determines Schlemm's canal integrity and identity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.278

Angiopoietin concentrations in diabetic retinopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.278

Increased intravitreal angiopoietin-2 levels associated with rhegmatogenous retinal detachment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.278

Circulating angiopoietin-2, its soluble receptor Tie-2, and mortality in the general population

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.278

Predictive value of circulating angiopoietin-2 for endothelial damage-related complications in allogeneic hematopoietic stem cell transplantation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.278

Angiopoietin-2 in acute myocardial infarction complicated by cardiogenic shock--a biomarker substudy of the IABP-SHOCK II-Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.278

Angiopoietin-2, marker and mediator of endothelial activation with prognostic significance early after trauma?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.278

The role of angiogenic factors in predicting clinical outcome in severe bacterial infection in Malawian children

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.278

Plasma angiopoietin-1 is lower after ischemic stroke and associated with major disability but not stroke incidence.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.278

Angiopoietin-1 is associated with cerebral vasospasm and delayed cerebral ischemia in subarachnoid hemorrhage

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.278

High Angiopoietin-1 levels predict a good functional outcome within 72 h of an aneurysmal subarachnoid hemorrhage: A prospective study from a single center.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.278

Disturbed balance between serum levels of receptor tyrosine kinases Tie-1, Tie-2 and angiopoietins in systemic sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.278

Angiopoietin-2 Serum Levels Improve Noninvasive Fibrosis Staging in Chronic Hepatitis C: A Fibrogenic-Angiogenic Link

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.278

Elevated plasma thrombomodulin and angiopoietin-2 predict the development of acute kidney injury in patients with acute myocardial infarction.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.278

Angiopoietin-2 as a Prognostic Biomarker of Major Adverse Cardiovascular Events and All-Cause Mortality in Chronic Kidney Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.278

Synergistic effect of vascular endothelial growth factor and angiopoietin-2 on progression free survival in multiple myeloma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.278

Circulating Ang-2 mRNA expression levels: looking ahead to a new prognostic factor for NSCLC [corrected]

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.278

High-circulating Tie2 Is Associated With Pathologic Complete Response to Chemotherapy and Antiangiogenic Therapy in Breast Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.278

Prognostic value of angiopoietin-2 for death risk stratification in patients with metastatic colorectal carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.278

Prospective evaluation of plasma levels of ANGPT2, TuM2PK, and VEGF in patients with renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.278

Pro-angiogenic cytokines for prediction of outcomes in patients with advanced hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.278

Angiopoietin-2 plasma dosage predicts time to first treatment and overall survival in chronic lymphocytic leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.278

Serum angiopoietin-2 and soluble VEGF receptor 2 are surrogate markers for plasma leakage in patients with acute dengue virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.278

Plasma angiopoietin-2 outperforms other markers of endothelial injury in prognosticating pediatric ARDS mortality.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.278

A high angiopoietin-2/angiopoietin-1 ratio is associated with a high risk of septic shock in patients with febrile neutropenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.278

The temporal kinetics of circulating angiopoietin levels in children with sepsis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.278

Angiopoietin-2 associations with the underlying infection and sepsis severity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.278

Angiopoietin-2 is increased in severe sepsis: correlation with inflammatory mediators

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.278

Circulating angiopopietin-1 correlates with the clinical course of multiple organ dysfunction syndrome and mortality in patients with severe sepsis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.278

Prognostic significance of the angiopoietin-2/angiopoietin-1 and angiopoietin-1/Tie-2 ratios for early sepsis in an emergency department

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.278

Plasma angiopoietin-2 in clinical acute lung injury: prognostic and pathogenetic significance

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.278

Ratio of angiopoietin-2 to angiopoietin-1 as a predictor of mortality in acute lung injury patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.278

Angiopoietin-2 in acute liver failure.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.278

Vascular endothelial hyperpermeability induces the clinical symptoms of Clarkson disease (the systemic capillary leak syndrome).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.278

Using angiogenic factors and their soluble receptors to predict organ dysfunction in patients with disseminated intravascular coagulation associated with severe trauma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.278

Angiogenic factors and their soluble receptors predict organ dysfunction and mortality in post-cardiac arrest syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.278

Angiopoietin-2 in patients requiring renal replacement therapy in the ICU: relation to acute kidney injury, multiple organ dysfunction syndrome and outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.278

Early angiopoietin-2 levels after onset predict the advent of severe pancreatitis, multiple organ failure, and infectious complications in patients with acute pancreatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.278

Angiopoietin-2, a regulator of vascular permeability in inflammation, is associated with persistent organ failure in patients with acute pancreatitis from the United States and Germany.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.278

A clinicopathological correlation of the expression of the angiopoietin-Tie-2 receptor pathway in the brain of adults with Plasmodium falciparum malaria

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.278

Platelet activation determines angiopoietin-1 and VEGF levels in malaria: implications for their use as biomarkers

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.278

Angiopoietin-2 levels are associated with retinopathy and predict mortality in Malawian children with cerebral malaria: a retrospective case-control study*

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.278

Plasma levels of angiopoietin-1 and -2 predict cerebral malaria outcome in Central India

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.278

Angiopoietin-2 in adults with congenital heart disease and heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.278

Angiopoietin-2 and outcome in patients with acute decompensated heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.278

Serum angiopoietin-2 and CRP levels during COPD exacerbations.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.278

Evaluation of angiopoietin 1 and 2, vascular endothelial growth factor, and tumor necrosis factor alpha levels in asthmatic children.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.278

Angiopoietin-2 concentration in serum is associated with severe asthma phenotype

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.278

Plasma vascular endothelial growth factor, angiopoietin-1, and angiopoietin-2 in diabetes: implications for cardiovascular risk and effects of multifactorial intervention

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.278

Serum angiopoietin-2 is associated with angiopathy in type 2 diabetes mellitus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.278

Angiopoietin-2 deficiency decelerates age-dependent vascular changes in the mouse retina

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.278

Decreased hypoxia-induced neovascularization in angiopoietin-2 heterozygous knockout mouse through reduced MMP activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.278

Retinal overexpression of angiopoietin-2 mimics diabetic retinopathy and enhances vascular damages in hyperglycemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.278

Angiopoietin 1 inhibits ocular neovascularization and breakdown of the blood-retinal barrier.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.278

A phase 1b, open-label study of trebananib plus bevacizumab or motesanib in patients with solid tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.278

A Phase I First-in-Human Study of Nesvacumab (REGN910), a Fully Human Anti-Angiopoietin-2 (Ang2) Monoclonal Antibody, in Patients with Advanced Solid Tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.278

Targeting key angiogenic pathways with a bispecific CrossMAb optimized for neovascular eye diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.278

Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.278

Altiratinib Inhibits Tumor Growth, Invasion, Angiogenesis, and Microenvironment-Mediated Drug Resistance via Balanced Inhibition of MET, TIE2, and VEGFR2

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.278

A phase I study of oral ARRY-614, a p38 MAPK/Tie2 dual inhibitor, in patients with low or intermediate-1 risk myelodysplastic syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.278

Double antiangiogenic protein, DAAP, targeting VEGF-A and angiopoietins in tumor angiogenesis, metastasis, and vascular leakage

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.278

Dual angiopoietin-2 and VEGFA inhibition elicits antitumor immunity that is enhanced by PD-1 checkpoint blockade.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.278

Structural basis of Tie2 activation and Tie2/Tie1 heterodimerization.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.278

Dimerization of Tie2 mediated by its membrane-proximal FNIII domains

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.278

Normalization of Tumor Vessels by Tie2 Activation and Ang2 Inhibition Enhances Drug Delivery and Produces a Favorable Tumor Microenvironment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.278

A human monoclonal anti-ANG2 antibody leads to broad antitumor activity in combination with VEGF inhibitors and chemotherapy agents in preclinical models

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.278

Structural basis for angiopoietin-1-mediated signaling initiation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.278

The Conformation of the Epidermal Growth Factor Receptor Transmembrane Domain Dimer Dynamically Adapts to the Local Membrane Environment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.278

Poor glycemic control associates with high intravitreal angiopoietin-2 levels in patients with diabetic retinopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.278

Angiopoietin-2 Serum Levels Are Elevated in Patients With Liver Cirrhosis and Hepatocellular Carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.278

Leukocyte extravasation and vascular permeability are each controlled in vivo by different tyrosine residues of VE-cadherin

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.278

Angiopoietin-1 regulates endothelial cell survival through the phosphatidylinositol 3'-Kinase/Akt signal transduction pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.278

Hypoxia and vascular endothelial growth factor selectively up-regulate angiopoietin-2 in bovine microvascular endothelial cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.278

Angiopoietin-2 functions as a Tie2 agonist in tumor models, where it limits the effects of VEGF inhibition

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.278

In vivo actions of angiopoietins on quiescent and remodeling blood and lymphatic vessels in mouse airways and skin

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.278

Targeted massively parallel sequencing of angiosarcomas reveals frequent activation of the mitogen activated protein kinase pathway

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.278

Increased vascularization in mice overexpressing angiopoietin-1

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.278

Transcriptional and post‐translation regulation of the Tiel receptor by fluid shear stress changes in vascular endothelial cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.278

Angiopoietin-2 levels predict mortality in CKD patients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.278

Angiopoietin-1 gene transfer improves impaired wound healing in genetically diabetic mice without increasing VEGF expression

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.278

Different effects of angiopoietin-2 in different vascular beds: new vessels are most sensitive.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.278

Anti-angiopoietin therapy with trebananib for recurrent ovarian cancer (TRINOVA-1): a randomised, multicentre, double-blind, placebo-controlled phase 3 trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.278

Differential expression of Tie-2 receptors and angiopoietins in response to in vivo hypoxia in rats

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.278

Vitreous levels of angiopoietin-1 and angiopoietin-2 in eyes with retinopathy of prematurity

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.278

Angiopoietin-2 is highly correlated with inflammation and disease activity in recent-onset rheumatoid arthritis and could be predictive for cardiovascular disease.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.278

Overexpression of angiopoietin-2 in rats and patients with liver fibrosis. Therapeutic consequences of its inhibition

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.278

Prognostic impact of angiopoietin-2 in multiple myeloma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.278

Expression of angiopoietins and vascular endothelial growth factors and their clinical significance in acute myeloid leukemia

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.278

Angiopoietin-2 is increased in septic shock: Evidence for the existence of a circulating factor stimulating its release from human monocytes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.278

The absence of angiopoietin-2 leads to abnormal vascular maturation and persistent proliferative retinopathy.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.278

Impaired pericyte recruitment and abnormal retinal angiogenesis as a result of angiopoietin-2 overexpression.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.278

Randomized, double-blind, placebo-controlled phase II study of AMG 386 combined with weekly paclitaxel in patients with recurrent ovarian cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.278

Structure of the Tie2 RTK domain: self-inhibition by the nucleotide binding loop, activation loop, and C-terminal tail

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRD.2016.278

Protective role of COMP-Ang1 in ischemic rat brain.

31 March 2020

1 reference

12 December 2020

Predominant expression of a receptor tyrosine kinase, TIE, in hematopoietic stem cells and B cells

1 reference

12 December 2020

Variable Somatic TIE2 Mutations in Half of Sporadic Venous Malformations

1 reference

12 December 2020

MEDI3617, a human anti-angiopoietin 2 monoclonal antibody, inhibits angiogenesis and tumor growth in human tumor xenograft models

1 reference

12 December 2020

Angiopoietin-1 guides directional angiogenesis through integrin αvβ5 signaling for recovery of ischemic retinopathy.

1 reference

12 December 2020

Kinetics of vascular normalization by VEGFR2 blockade governs brain tumor response to radiation: role of oxygenation, angiopoietin-1, and matrix metalloproteinases.

1 reference

12 December 2020

Admission angiopoietin levels in children with septic shock.

1 reference

12 December 2020

Angiopoietin-1/Tie-2 activation contributes to vascular survival and tumor growth during VEGF blockade

1 reference

12 December 2020

tek, a novel tyrosine kinase gene located on mouse chromosome 4, is expressed in endothelial cells and their presumptive precursors

1 reference

12 December 2020

The Tie receptor tyrosine kinase is expressed by human hematopoietic progenitor cells and by a subset of megakaryocytic cells.

1 reference

12 December 2020

Endothelial cell-derived angiopoietin-2 is a therapeutic target in treatment-naive and bevacizumab-resistant glioblastoma

1 reference

12 December 2020

Angiopoietin-2 serum levels correlate with severity, early onset and cardiovascular disease in patients with rheumatoid arthritis

1 reference

12 December 2020

Diagnostic and prognostic potential of serum angiopoietin-2 expression in human breast cancer

1 reference

12 December 2020

Identifiers

DOI

10.1038/NRD.2016.278

1 reference

11 September 2017

1 reference

PubMed ID

28529319